Evidence map›Paper›PMID 40985427›Full record

ArticleJournal of fungi (Basel, Switzerland)2025

Antimicrobial Peptides Act-6 and Act 8-20 Derived from Scarabaeidae Cecropins Exhibit Differential Antifungal Activity.

Melissa Rodríguez, Lily J Toro, Carolina Firacative, Beatriz L Gómez, Bruno Rivas-Santiago, David Andreu, Jhon C Castaño, German A Téllez, Julián E Muñoz

Abstract read
In one paragraph

Article in Journal of fungi (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Melissa RodríguezStudies in Translational Microbiology and Emerging Diseases (MICROS) Research Group, Translational Medicine Institute, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia.ORCID 0000-0001-7713-3598
Lily J ToroCenter of Biomedical Research, Group of Molecular Immunology, Universidad del Quindío, Armenia 630001, Quindío, Colombia.ORCID 0000-0001-7906-1997
Carolina FiracativeStudies in Translational Microbiology and Emerging Diseases (MICROS) Research Group, Translational Medicine Institute, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia.ORCID 0000-0001-7547-5172
Beatriz L GómezStudies in Translational Microbiology and Emerging Diseases (MICROS) Research Group, Translational Medicine Institute, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia.ORCID 0000-0002-6641-1924
Bruno Rivas-SantiagoBiomedical Research Unit-Zacatecas, Mexican Institute for Social Security-IMSS, Zacatecas 98000, Mexico.ORCID 0000-0002-1521-1519
David AndreuProteomics and Protein Chemistry Unit, Department of Medicine and Life Sciences, Pompeu Fabra University, Barcelona Biomedical Research Park, Dr. Aiguader 88, 08003 Barcelona, Spain.ORCID 0000-0002-6317-6666
Jhon C CastañoCenter of Biomedical Research, Group of Molecular Immunology, Universidad del Quindío, Armenia 630001, Quindío, Colombia.ORCID 0000-0002-7639-3053
German A TéllezCenter of Biomedical Research, Group of Molecular Immunology, Universidad del Quindío, Armenia 630001, Quindío, Colombia.ORCID 0000-0002-3057-9290
Julián E MuñozStudies in Translational Microbiology and Emerging Diseases (MICROS) Research Group, Translational Medicine Institute, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, Colombia.ORCID 0000-0003-4495-7077

Funding

Colombia's Ministry of Science, Technology, and Innovation (MIN-CIENCIAS) 1113-668447 under contract 859-2019, research project call 844-2019
6 · The paper itself

Abstract

The number of fungal infections is steadily increasing, with considerable morbidity and mortality. Additionally, antifungal resistance is a growing concern, highlighting the need to develop new treatment options. One alternative is the use of antimicrobial peptides (AMPs). The aim of this study was to assess the in vitro and in vivo antifungal activity of designed short AMPs, Act-6 and Act 8-20, derived from cecropin transcripts of beetles from the family Scarabaeidae, against eight reference strains of the pathogenic yeasts

Indexed as

antifungal therapyantimicrobial peptidesantimicrobial resistanceCandidaCryptococcusdung beetle

Identifiers

PMID40985427
PMCPMC12301061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.